Viracept
nelfinavir
Table of contents
Withdrawn
This medicine is now withdrawn from use in the European Union.
Overview
The marketing authorisation for Viracept has not been renewed by the marketing-authorisation holder and is now withdrawn.
This EPAR was last updated on 10/06/2014
Authorisation details
| Product details | |
|---|---|
| Name |
Viracept
|
| Agency product number |
EMEA/H/C/000164
|
| Active substance |
nelfinavir
|
| International non-proprietary name (INN) or common name |
nelfinavir
|
| Therapeutic area (MeSH) |
HIV Infections
|
| Anatomical therapeutic chemical (ATC) code |
J05AE04
|
| Publication details | |
|---|---|
| Marketing-authorisation holder |
Roche Registration Ltd.
|
| Revision |
25
|
| Date of issue of marketing authorisation valid throughout the European Union |
22/01/1998
|
| Contact address | |
Product information
23/01/2013 Viracept - EMEA/H/C/000164 - N/0121
Contents
- Annex I - Summary of product characteristics
- Annex IIA - Manufacturing-authorisation holder responsible for batch release
- Annex IIB - Conditions of the marketing authorisation
- Annex IIIA - Labelling
- Annex IIIB - Package leaflet
Please note that the size of the above document can exceed 50 pages.
You are therefore advised to be selective about which sections or pages you wish to print.
Pharmacotherapeutic group
Pharmacotherapeutic group
Antivirals for systemic use
Therapeutic indication
Therapeutic indication
Viracept is indicated in antiretroviral combination treatment of human-immunodeficiency-virus (HIV-1)-infected adults, adolescents and children of three years of age and older.
In protease-inhibitor (PI)-experienced patients, the choice of nelfinavir should be based on individual viral resistance testing and treatment history.